Antibiotic resistance and gyrA mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for Helicobacter pylori in penicillin allergic patients
出版年份 2017 全文链接
标题
Antibiotic resistance and gyrA mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for Helicobacter pylori in penicillin allergic patients
作者
关键词
-
出版物
United European Gastroenterology Journal
Volume 5, Issue 6, Pages 796-804
出版商
SAGE Publications
发表日期
2017-01-22
DOI
10.1177/2050640616688995
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report
- (2016) P Malfertheiner et al. GUT
- Helicobacter pyloriin First Nations and Recent Immigrant Populations in Canada
- (2016) Nicola L Jones et al. CANADIAN JOURNAL OF GASTROENTEROLOGY
- Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies forHelicobacter pyloriStrains Containing thegyrAMutation
- (2015) Hideki Mori et al. HELICOBACTER
- Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study
- (2015) Hideki Mori et al. United European Gastroenterology Journal
- Prevalence and characteristics of reported penicillin allergy in an urban outpatient adult population
- (2014) Stephanie Albin et al. ALLERGY AND ASTHMA PROCEEDINGS
- Helicobacter Pylori First-Line and Rescue Treatments in the Presence of Penicillin Allergy
- (2014) Javier P. Gisbert et al. DIGESTIVE DISEASES AND SCIENCES
- Eradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin
- (2014) Takahisa Furuta et al. INTERNAL MEDICINE
- Changes in the first lineHelicobacter pylorieradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (TokyoHelicobacter pyloristudy group)
- (2014) Takashi Kawai et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Trends of Second-Line Eradication Therapy forHelicobacter pyloriin Japan: A Multicenter Study in the Tokyo Metropolitan Area
- (2013) Daisuke Asaoka et al. HELICOBACTER
- Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan
- (2013) Kazunari Murakami et al. JOURNAL OF GASTROENTEROLOGY
- Sitafloxacin-based third-line rescue regimens forHelicobacter pyloriinfection in Japan
- (2013) Takahisa Furuta et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Helicobacter pylori Resistance to Rifabutin in the Last 7 Years
- (2011) Toshihiro Nishizawa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of Sitafloxacin-Based Rescue Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies
- (2011) Juntaro Matsuzaki et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Genotypic Resistance inHelicobacter pyloriStrains Correlates with Susceptibility Test and Treatment Outcomes after Levofloxacin- and Clarithromycin-Based Therapies
- (2010) Jyh-Ming Liou et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Helicobacter pylorieradication therapy
- (2010) Hidekazu Suzuki et al. Future Microbiology
- Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin
- (2010) Makoto Sasaki et al. JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION
- Homology model of the DNA gyrase enzyme of Helicobacter pylori, a target of quinolone-based eradication therapy
- (2010) Juntaro Matsuzaki et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Self-reported Antibiotic Allergy Incidence and Prevalence: Age and Sex Effects
- (2009) Eric Macy et al. AMERICAN JOURNAL OF MEDICINE
- Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin
- (2009) J.P. Gisbert et al. DIGESTIVE AND LIVER DISEASE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More